ALX

$228.75

$-3.01

Alexander's, Inc. is a real estate investment trust which has seven properties in the greater New York City metropolitan area.

Next Earnings

2026-01-11

Beta

0.789

Average Volume

61482

Market Cap

1168292588

Last Dividend

18

CIK

0000003499

ISIN

US0147521092

CUSIP

014752109

CEO

Steven Roth

Sector

Real Estate

Industry

REIT - Retail

Full Time Employees

90

IPO Date

1973-02-21

Status

Active

Latest News

Title Headline Publisher Date
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced its participation in the 44th Annual J.P. GlobeNewsWire 2026-01-08 11:00:00
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – GlobeNewsWire 2026-01-08 08:30:00
Best Income Stocks to Buy for December 31st ALX, KFRC and BHP made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 31, 2025. Zacks Investment Research 2025-12-31 03:46:05
Alexander's Completes Restructuring of Retail Loan at 731 Lexington Avenue PARAMUS, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it has restructured the $300 million mortgage loan on the retail condominium of 731 Lexington Avenue in Manhattan. Under the terms of the restructuring, the existing loan was split into a $132.5 million senior “A-Note” accruing current interest at 7.00% per annum and a $167.5 million junior “C-Note” accruing interest at 4.55% per annum, with a new maturity date of December 23, 2035. GlobeNewsWire 2025-12-29 08:44:00
Alexander’s (NYSE:ALX) Sees Strong Trading Volume – Here’s What Happened Alexander's, Inc. (NYSE: ALX - Get Free Report) saw unusually-high trading volume on Friday. Approximately 44,573 shares were traded during trading, an increase of 1% from the previous session's volume of 44,283 shares.The stock last traded at $217.3350 and had previously closed at $218.16. Analysts Set New Price Targets A number of brokerages have recently Defense World 2025-12-28 02:55:06
Alexander’s (NYSE:ALX) Sees Strong Trading Volume – Here’s What Happened Alexander's, Inc. (NYSE: ALX - Get Free Report) shares saw an uptick in trading volume on Friday. 54,369 shares traded hands during trading, an increase of 25% from the previous session's volume of 43,607 shares.The stock last traded at $217.48 and had previously closed at $218.56. Analysts Set New Price Targets ALX has been the Defense World 2025-12-21 03:32:50
Alexander's: Fed Tailwinds Drive FFO Growth Alexander's, Inc. is a commercial REIT managing five properties in New York, with Bloomberg accounting for 60% of revenues. ALX's Q3 2025 results show FFO growth of 2.5%, principally driven by lower funding costs, which more than offset a drop in net operating income. Looking ahead to Q4 2025 and 2026, I see ALX's net operating income returning to growth thanks to recent occupancy gains. Seeking Alpha 2025-12-19 11:37:24
Alexander’s (NYSE:ALX) Shares Cross Below 200 Day Moving Average – Here’s Why Shares of Alexander's, Inc. (NYSE: ALX - Get Free Report) passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $229.44 and traded as low as $214.80. Alexander's shares last traded at $215.8270, with a volume of 80,019 shares traded. Wall Street Analyst Weigh In A number Defense World 2025-12-16 05:30:58
Alexander's Completes $175 Million Refinancing of Rego Park II PARAMUS, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it has completed a $175 million refinancing of its 615,000 square foot Rego Park II shopping center located in Queens, New York. The interest-only loan is at SOFR plus 2.00%, currently 5.82%, and matures in December 2030. GlobeNewsWire 2025-12-09 08:59:00
Dividends Up To 20% Wall Street Says You Should Sell We contrarians follow Wall Street analysts because we like to fade their opinions! Forbes 2025-11-22 09:35:07
ALX Oncology to Present at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in both the Jefferies Global Healthcare Conference in London and Piper Sandler 37th Annual Global Healthcare Conference in New York. GlobeNewsWire 2025-11-18 11:00:00
Best Income Stocks to Buy for Nov. 13 ALX, PFBC and WFRD made it to the Zacks Rank #1 (Strong Buy) income stocks list on Nov. 13, 2025. Zacks Investment Research 2025-11-13 04:56:07
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. GlobeNewsWire 2025-11-07 08:15:00
Is Alexander's (ALX) Outperforming Other Finance Stocks This Year? Here is how Alexander's (ALX) and Affiliated Managers Group (AMG) have performed compared to their sector so far this year. Zacks Investment Research 2025-11-06 10:40:16
ALX Oncology (ALXO) Expected to Announce Earnings on Friday ALX Oncology (NASDAQ: ALXO - Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Friday, November 7th. Analysts expect ALX Oncology to post earnings of ($0.37) per share for the quarter. Interested persons may review the information on the company's upcoming Q3 2025 earningreport for the latest details Defense World 2025-11-06 01:02:44
Alexander's Announces Third Quarter Financial Results PARAMUS, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2025 today and reported: GlobeNewsWire 2025-11-03 09:17:00
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its third quarter 2025 financial results and provide a business update on Friday, November 7th, 2025, before market open. GlobeNewsWire 2025-10-30 08:30:00
Alexander's Breaks Above 8% Yield Territory In trading on Wednesday, shares of Alexander's were yielding above the 8% mark based on its quarterly dividend (annualized to $18), with the stock changing hands as low as $224.25 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. Forbes 2025-10-29 15:30:03
Alexander's Declares Quarterly $4.50 Dividend on Common Shares PARAMUS, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on November 28, 2025 to stockholders of record on November 10, 2025. GlobeNewsWire 2025-10-29 13:37:00
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference -Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors GlobeNewsWire 2025-10-23 12:30:00
Alexander's Announces Third Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call PARAMUS, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2025 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 3, 2025, before the New York Stock Exchange opens. GlobeNewsWire 2025-10-21 13:23:00

SEC Filings

Type Filing Date Accepted Date Link
8-K 2025-12-29 2025-12-29 View Filing
8-K 2025-12-09 2025-12-09 View Filing
10-Q 2025-11-03 2025-11-03 View Filing
10-Q 2025-08-04 2025-08-04 View Filing
4 2025-05-23 2025-05-23 View Filing
4 2025-05-23 2025-05-23 View Filing
4 2025-05-23 2025-05-23 View Filing
4 2025-05-23 2025-05-23 View Filing
4 2025-05-23 2025-05-23 View Filing
4 2025-05-23 2025-05-23 View Filing
4 2025-05-23 2025-05-23 View Filing
8-K 2025-05-22 2025-05-22 View Filing
10-Q 2025-05-05 2025-05-05 View Filing
ARS 2025-04-08 2025-04-08 View Filing
DEFA14A 2025-04-08 2025-04-08 View Filing
DEF 14A 2025-04-08 2025-04-08 View Filing
10-K 2025-02-10 2025-02-10 View Filing
8-K 2024-12-30 2024-12-30 View Filing
10-Q 2024-11-04 2024-11-04 View Filing
8-K 2024-09-30 2024-09-30 View Filing
10-Q 2024-08-05 2024-08-05 View Filing
8-K 2024-06-12 2024-06-11 View Filing
4 2024-05-24 2024-05-24 View Filing
4 2024-05-24 2024-05-24 View Filing
4 2024-05-24 2024-05-24 View Filing
4 2024-05-24 2024-05-24 View Filing
4 2024-05-24 2024-05-24 View Filing
4 2024-05-24 2024-05-24 View Filing
4 2024-05-24 2024-05-24 View Filing
4 2024-05-24 2024-05-24 View Filing
8-K 2024-05-23 2024-05-23 View Filing
10-Q 2024-05-06 2024-05-06 View Filing
ARS 2024-04-09 2024-04-09 View Filing
DEFA14A 2024-04-09 2024-04-09 View Filing
DEF 14A 2024-04-09 2024-04-09 View Filing
SC 13G/A 2024-02-13 2024-02-13 View Filing
10-K 2024-02-12 2024-02-12 View Filing
SC 13G/A 2024-02-06 2024-02-06 View Filing

Algorithm Performance

Upgrade To Premium for Full Access
Algorithm Profit/Loss Profit Factor # Trades Sharpe Sortino Efficiency
Larry Williams PercentR Strategy 8.05% 1 166 0.02 0.05 11.66
Williams PercentR Strategy 8.04% 1 282 0.01 0.05 11.65
Bollinger Bands Strategy 6.89% 1 92 0.01 0.06 10.5
xxxxxxxxxxxxxxxx xxxxxx% xxxx xx x xxxx xxxx
xxx xxxxxxx% x xxx x xxxx xxxx
xxxxxxxxxx xxxxxxx% x xxx xxxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxxx xxxx xxxx
xxxxxxxxx xxxxxxx% x xxx xxxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxx% x xxx xxxxx x xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xxx xxxxx x xxxx
xxxxxxxxx xxxxxxx% x xxx xxxxx x xxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx x xxxxx xxxxx xxxx
xxxxxxxxx xxxxxx% xxxx xxx xxxxx x xxx
xxxxxxxxxxxxxxx xxxxxxx% x xx xxxxx x xxxx
xxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx x xxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx x xxxx
xxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx x
xxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxx xxxxxxxx% xxxx x xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xx xxxxx xxxxx xxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxx xxxxxxxx% x xxx xxxxx xxxxx xxxxx
xxxx xxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxx xxxxx